DISCOUNT OPTIONSSCHEIN - ELI LILLY & CO | Market Closed - Börse Stuttgart 15:00:53 2024-05-31 EDT | ||
| 1.02 EUR | -0.97% |
|
| 1 month | +7.37% | ||
| 3 months | +2.00% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 24-05-31 | 1.02 | -0.97% |
| 24-05-30 | 1.03 | +3.00% |
| 24-05-29 | 1 | -.--% |
| 24-05-28 | 1 | -0.99% |
| 24-05-27 | 1.01 | +2.02% |
Delayed Quote Börse Stuttgart
Last update May 31, 2024 at 03:00 pm
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | Morgan Stanley |
| WKN | ME8T1Q |
| ISIN | DE000ME8T1Q6 |
| Date issued | 2024-02-15 |
| Strike | 920 $ |
| Maturity | 2024-09-20 (111 Days) |
| Parity | 10 : 1 |
| Emission price | 0.58 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.29 € |
|---|---|
| Lowest since issue | 0.59 € |
| Spread | 0.04 € |
| Spread % | 3.51% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
820.3
USD
Average target price
852.5
USD
Spread / Average Target
+3.92%
- Stock Market
- Certificates
- Certificat
